Coronary microvascular disease
Conditions
Interventions
1:Shexiang Tongxin Droping Pills combined with other drug treatment group
2:Nicroandil combined with other drug treatment group
Sponsors
Beijing Anzhen Hosptial, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those with chest pain (including stable angina pectoris and unstable angina pectoris); 2) Those aged between 18 to 70 (contain patients aged 18 and 70); 3) Those with left ventricular eject fraction more than 50% assessed by transthoracic echocardiography; 4) Those with anxiety [7-item Generalized Anxiety Disorder Scale (GAD-7)>=5) ] and/or depression [9-item depression module from the Patient Health Questionnaire (PHQ9) >= 5]; 5) Those with no obvious stenosis (>50%) in the significant epicaridial artery, or with no more than 50% stenosis in the original PCI artery; 6) Those fully understand the research requirements and intervention procedures, and signed informed consent before the program; 7) Those comply all examination and follow-up protocol.
Exclusion criteria
Exclusion criteria: 1) Those with new-onset myocardial infarction within the latest 3-month; 2) Patients who had CABG; 3) Patients who are allergic or contraindicate to anti-platelet or anticoagulation drug, contrast, nicorandil or STDP; 4) Those with severe abnormal hematopoietic system, such as platelet counts 700*10^9/L and white blood cell counts = 3-fold of the upper limit of the normal reference); 8) Those with severe heart failure (NYHA classification >= III) ; 9) Those suffering from tumor and other disease that with life expectancy less 12 months; 10) Women who are pregnant or plan to be pregnant; 11) Those with acute infectious diseases and immune disorders; 12) Those unable to communicate due to cognitive impairment, auditory and visual impairment; 13) Patients who are participating in or plan to participate in another clinical trial; 14) Those with claustrophobia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| absolute myocardial blood flow;quantitive myocardial perfusion reserve;semiquantitive myocardial perfusion reserve index; | — |
Secondary
| Measure | Time frame |
|---|---|
| major adverse cardiovascular event;GAD-7 and PHQ9 scale;Quality of life (QOL) and angina pectoris occurrence;Inflammation index;oxidative stress index; | — |
Countries
China
Contacts
Public ContactXiantao Song
Department of Cardiology, Anzhen Hospital, Capital Medical University
Outcome results
None listed